<p>Immunocore Holdings PLC 赞助的 ADR（NASDAQ:IMCR - 获取免费报告）在周五达到了新的 52 周高点。该股最高交易价为 40.71 美元，最后交易价为 39.93 美元，成交量为 5771 股。该股此前收盘价为 40.22 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>增长选择：3 只低成本股票可能会翻倍</li>
</ul>
<p>多位股票分析师最近对该股发布了报告。摩根士丹利将 Immunocore 的目标价从 34.00 美元上调至 36.00 美元，并在 11 月 10 日的研究报告中给予该公司 “持平” 评级。Guggenheim 于 9 月 18 日星期四开始对 Immunocore 进行覆盖。他们对该公司给予了 “中性” 评级。HC Wainwright 在 10 月 22 日星期三重申了 “买入” 评级，并对 Immunocore 的目标价设定为 100.00 美元。Weiss Ratings 在 10 月 8 日星期三的报告中重新发布了对 Immunocore 的 “卖出（e+）” 评级。最后，Wall Street Zen 在 11 月 8 日星期六的研究报告中将 Immunocore 的评级从 “持有” 上调至 “买入”。七位投资分析师对该股给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Immunocore 的共识评级为 “适度买入”，平均目标价为 61.00 美元。</p>
<p><strong>阅读我们关于 Immunocore 的最新报告</strong></p>
<h2>Immunocore 股价下跌 3.2%</h2>
<ul>
<li>3 只快速增长的股票分析师认为价格将翻倍</li>
</ul>
<p>该公司的市值为 19.7 亿美元，市盈率为 -68.16，贝塔值为 0.77。该公司的速动比率为 5.97，流动比率为 6.00，债务股本比率为 0.99。该公司的 50 日移动平均线为 35.06 美元，200 日移动平均线为 34.23 美元。</p>
<p>Immunocore（NASDAQ:IMCR - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告每股收益（EPS）为 0.02 美元，超出市场共识预期的 -0.30 美元，超出幅度为 0.32 美元。该公司季度收入为 1.0369 亿美元，而分析师预期为 1.3729 亿美元。Immunocore 的股本回报率为 -7.67%，净利润率为 -7.70%。该公司的收入同比增长 29.2%。在去年同期，该公司每股收益为 0.17 美元。股票分析师预测 Immunocore Holdings PLC 赞助的 ADR 在本年度将发布 -0.94 美元的每股收益。</p>
<h2>Immunocore 的内部买卖</h2>
<ul>
<li>机构正在购买这 3 只股票，分析师一致认为</li>
</ul>
<p>在相关消息中，内部人士 David M. Berman 于 9 月 12 日星期五出售了 22,532 股 Immunocore 股票。该股票以平均价格 35.67 美元出售，总价值为 803,716.44 美元。此次出售已在与 SEC 的法律文件中披露，文件可在此链接查看。10.40% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近对该公司的持仓进行了调整。GAMMA Investing LLC 在第三季度将其在 Immunocore 的持仓增加了 51.6%。GAMMA Investing LLC 目前拥有 914 股该公司股票，价值 33,000 美元，此前在上个季度增持了 311 股。DNB Asset Management AS 在第三季度将其在 Immunocore 的持仓增加了 6.4%。DNB Asset Management AS 目前拥有 8,116 股该公司股票，价值 295,000 美元，此前在上个季度增持了 488 股。Virtus Investment Advisers LLC 在第二季度将其在 Immunocore 的持仓增加了 5.3%。Virtus Investment Advisers LLC 目前拥有 12,472 股该公司股票，价值 391,000 美元，此前在上个季度增持了 625 股。Orion Porfolio Solutions LLC 在第二季度将其在 Immunocore 的持仓增加了 4.5%。Orion Porfolio Solutions LLC 目前拥有 23,965 股该公司股票，价值 752,000 美元，此前在此期间增持了 1,031 股。最后，Assetmark Inc. 在第二季度将其在 Immunocore 的持仓增加了 3.7%。Assetmark Inc. 目前拥有 34,958 股该公司股票，价值 1,097,000 美元，此前在上个季度增持了 1,248 股。84.50% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Immunocore 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunocore Holdings plc 是一家商业阶段的生物技术公司，专注于开发用于治疗癌症、感染和自身免疫性疾病的免疫疗法。该公司提供 KIMMTRAK，用于治疗不可切除或转移性葡萄膜黑色素瘤的患者。它还开发其他肿瘤学项目，包括正在进行 2/3 期临床试验的 tebentafusp，用于治疗晚期皮肤黑色素瘤。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票超过 Immunocore</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>加密矿工会转向 AI 吗？关于 3 家关键参与者的最新消息</li>
<li>股息捕获策略：你需要知道的事项</li>
<li>Salesforce 股票像弹簧一样蓄势待发，准备反弹</li>
<li>什么是 SEC 备案？</li>
<li>Marvell 的反弹延续：数据中心和 AMZN 芯片推动股价上涨</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Immunocore 吗？</h2>
<p>在你考虑投资 Immunocore 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Immunocore 并不在名单上。</p>
<p>虽然 Immunocore 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMCR

<p>Immunocore Holdings PLC（纳斯达克代码：IMCR）达到了新的 52 周高点，交易价格高达 40.71 美元。分析师的评级各不相同，普遍共识为 “适度买入”，平均目标价为 61.00 美元。该公司报告的收益超出预期，收入同比增长 29.2%。内部人士和机构的活动显示出显著的股票交易。Immunocore 开发用于癌症和其他疾病的免疫疗法</p>

<p>Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) reached a new 52-week high on Friday . The stock traded as high as $40.71 and last traded at $39.93, with a volume of 5771 shares. The stock had previously closed at $40.22.</p>
<div class="lb-trans"><p>Immunocore Holdings PLC 赞助的 ADR（NASDAQ:IMCR - 获取免费报告）在周五达到了新的 52 周高点。该股最高交易价为 40.71 美元，最后交易价为 39.93 美元，成交量为 5771 股。该股此前收盘价为 40.22 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>增长选择：3 只低成本股票可能会翻倍</li>
</ul>
</div><p>A number of equities analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Immunocore from $34.00 to $36.00 and gave the company an &#34;equal weight&#34; rating in a research report on Monday, November 10th. Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They issued a &#34;neutral&#34; rating for the company. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, October 22nd. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Immunocore in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Immunocore from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $61.00.</p>
<div class="lb-trans"><p>多位股票分析师最近对该股发布了报告。摩根士丹利将 Immunocore 的目标价从 34.00 美元上调至 36.00 美元，并在 11 月 10 日的研究报告中给予该公司 “持平” 评级。Guggenheim 于 9 月 18 日星期四开始对 Immunocore 进行覆盖。他们对该公司给予了 “中性” 评级。HC Wainwright 在 10 月 22 日星期三重申了 “买入” 评级，并对 Immunocore 的目标价设定为 100.00 美元。Weiss Ratings 在 10 月 8 日星期三的报告中重新发布了对 Immunocore 的 “卖出（e+）” 评级。最后，Wall Street Zen 在 11 月 8 日星期六的研究报告中将 Immunocore 的评级从 “持有” 上调至 “买入”。七位投资分析师对该股给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Immunocore 的共识评级为 “适度买入”，平均目标价为 61.00 美元。</p>
</div><p><strong>Read Our Latest Report on Immunocore</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Immunocore 的最新报告</strong></p>
</div><h2>Immunocore Trading Down 3.2%</h2>
<div class="lb-trans"><h2>Immunocore 股价下跌 3.2%</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师认为价格将翻倍</li>
</ul>
</div><p>The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -68.16 and a beta of 0.77. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The firm's 50 day moving average is $35.06 and its 200 day moving average is $34.23.</p>
<div class="lb-trans"><p>该公司的市值为 19.7 亿美元，市盈率为 -68.16，贝塔值为 0.77。该公司的速动比率为 5.97，流动比率为 6.00，债务股本比率为 0.99。该公司的 50 日移动平均线为 35.06 美元，200 日移动平均线为 34.23 美元。</p>
</div><p>Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The company had revenue of $103.69 million for the quarter, compared to analysts' expectations of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The firm's revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 earnings per share. Equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.</p>
<div class="lb-trans"><p>Immunocore（NASDAQ:IMCR - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告每股收益（EPS）为 0.02 美元，超出市场共识预期的 -0.30 美元，超出幅度为 0.32 美元。该公司季度收入为 1.0369 亿美元，而分析师预期为 1.3729 亿美元。Immunocore 的股本回报率为 -7.67%，净利润率为 -7.70%。该公司的收入同比增长 29.2%。在去年同期，该公司每股收益为 0.17 美元。股票分析师预测 Immunocore Holdings PLC 赞助的 ADR 在本年度将发布 -0.94 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Immunocore</h2>
<div class="lb-trans"><h2>Immunocore 的内部买卖</h2>
</div><ul>
<li>Institutions are Buying These 3 Stocks and Analysts Agree</li>
</ul>
<div class="lb-trans"><ul>
<li>机构正在购买这 3 只股票，分析师一致认为</li>
</ul>
</div><p>In related news, insider David M. Berman sold 22,532 shares of Immunocore stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 David M. Berman 于 9 月 12 日星期五出售了 22,532 股 Immunocore 股票。该股票以平均价格 35.67 美元出售，总价值为 803,716.44 美元。此次出售已在与 SEC 的法律文件中披露，文件可在此链接查看。10.40% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company's stock valued at $33,000 after acquiring an additional 311 shares in the last quarter. DNB Asset Management AS lifted its holdings in shares of Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company's stock valued at $295,000 after purchasing an additional 488 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Immunocore by 5.3% in the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company's stock valued at $391,000 after purchasing an additional 625 shares in the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Immunocore by 4.5% in the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock worth $752,000 after buying an additional 1,031 shares during the period. Finally, Assetmark Inc. grew its holdings in shares of Immunocore by 3.7% during the second quarter. Assetmark Inc. now owns 34,958 shares of the company's stock valued at $1,097,000 after buying an additional 1,248 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。GAMMA Investing LLC 在第三季度将其在 Immunocore 的持仓增加了 51.6%。GAMMA Investing LLC 目前拥有 914 股该公司股票，价值 33,000 美元，此前在上个季度增持了 311 股。DNB Asset Management AS 在第三季度将其在 Immunocore 的持仓增加了 6.4%。DNB Asset Management AS 目前拥有 8,116 股该公司股票，价值 295,000 美元，此前在上个季度增持了 488 股。Virtus Investment Advisers LLC 在第二季度将其在 Immunocore 的持仓增加了 5.3%。Virtus Investment Advisers LLC 目前拥有 12,472 股该公司股票，价值 391,000 美元，此前在上个季度增持了 625 股。Orion Porfolio Solutions LLC 在第二季度将其在 Immunocore 的持仓增加了 4.5%。Orion Porfolio Solutions LLC 目前拥有 23,965 股该公司股票，价值 752,000 美元，此前在此期间增持了 1,031 股。最后，Assetmark Inc. 在第二季度将其在 Immunocore 的持仓增加了 3.7%。Assetmark Inc. 目前拥有 34,958 股该公司股票，价值 1,097,000 美元，此前在上个季度增持了 1,248 股。84.50% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Immunocore Company Profile</h2>
<div class="lb-trans"><h2>Immunocore 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.</p>
<div class="lb-trans"><p>Immunocore Holdings plc 是一家商业阶段的生物技术公司，专注于开发用于治疗癌症、感染和自身免疫性疾病的免疫疗法。该公司提供 KIMMTRAK，用于治疗不可切除或转移性葡萄膜黑色素瘤的患者。它还开发其他肿瘤学项目，包括正在进行 2/3 期临床试验的 tebentafusp，用于治疗晚期皮肤黑色素瘤。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Immunocore</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
<li>What is a SEC Filing?</li>
<li>Marvell's Rally Extends: Data Centers and AMZN Chips Boost Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Immunocore</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>加密矿工会转向 AI 吗？关于 3 家关键参与者的最新消息</li>
<li>股息捕获策略：你需要知道的事项</li>
<li>Salesforce 股票像弹簧一样蓄势待发，准备反弹</li>
<li>什么是 SEC 备案？</li>
<li>Marvell 的反弹延续：数据中心和 AMZN 芯片推动股价上涨</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunocore Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Immunocore 吗？</h2>
</div><p>Before you consider Immunocore, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Immunocore 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Immunocore 并不在名单上。</p>
</div><p>While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunocore 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunocore（纳斯达克股票代码：IMCR）创下新的 1 年高点 - 以下是发生的情况